Literature DB >> 20974825

Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Alexandra G Fraga1, Andrea Cruz, Teresa G Martins, Egídio Torrado, Margarida Saraiva, Daniela R Pereira, Wayne M Meyers, Françoise Portaels, Manuel T Silva, António G Castro, Jorge Pedrosa.   

Abstract

Buruli ulcer is a neglected infectious disease caused by Mycobacterium ulcerans and is characterized by necrotic cutaneous lesions induced by the exotoxin mycolactone. Despite evidence of Th1-mediated protective immunity, M. ulcerans infection has been associated with systemic immunosuppression. We show that early during mouse infection with either mycolactone-positive or negative strains, pathogen-specific gamma interferon (IFN-γ)-producing T cells developed in the draining lymph node (DLN). CD4(+) cells migrated to the infection foci, but progressive infection with virulent M. ulcerans led to the local depletion of recruited cells. Moreover, dissemination of virulent M. ulcerans to the DLN was accompanied by extensive DLN apoptotic cytopathology, leading to depletion of CD4(+) T cells and abrogation of IFN-γ expression. Advanced footpad infection with virulent M. ulcerans did not induce increased susceptibility to systemic coinfection by Listeria monocytogenes. These results show that infection with M. ulcerans efficiently triggers a mycobacterium-specific T-cell response in the DLN and that progression of infection with highly virulent M. ulcerans leads to a local and regional suppression of that immune response, but without induction of systemic immunosuppression. These results suggest that prophylactic and/or therapeutic interventions to prevent dissemination of M. ulcerans to DLN during the early phase of infection would contribute for the maintenance of protective immunity and disease control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974825      PMCID: PMC3019874          DOI: 10.1128/IAI.00820-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  74 in total

Review 1.  Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse.

Authors:  G J Bancroft; R D Schreiber; E R Unanue
Journal:  Immunol Rev       Date:  1991-12       Impact factor: 12.988

2.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.

Authors:  K M George; D Chatterjee; G Gunawardana; D Welty; J Hayman; R Lee; P L Small
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

Review 3.  Mycobacterium ulcerans disease.

Authors:  Tjip S van der Werf; Ymkje Stienstra; R Christian Johnson; Richard Phillips; Ohene Adjei; Bernhard Fleischer; Mark H Wansbrough-Jones; Paul D R Johnson; Françoise Portaels; Winette T A van der Graaf; Kingsley Asiedu
Journal:  Bull World Health Organ       Date:  2005-11-10       Impact factor: 9.408

4.  Ulcerative cutaneous mycobacteriosis due to Mycobacterium ulcerans: report of two Mexican cases.

Authors:  Josefa Novales-Santa Coloma; Gisela Navarrete-Franco; Pedro Iribe; Larissa Dorina López-Cepeda
Journal:  Int J Lepr Other Mycobact Dis       Date:  2005-03

5.  Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo.

Authors:  Holger Hackstein; Timucin Taner; Alan F Zahorchak; Adrian E Morelli; Alison J Logar; Andre Gessner; Angus W Thomson
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

6.  BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda.

Authors: 
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

7.  Association of HIV infection and Mycobacterium ulcerans disease in Benin.

Authors:  Roch C Johnson; Fabienne Nackers; Judith R Glynn; Elisa de Biurrun Bakedano; Claude Zinsou; Julia Aguiar; René Tonglet; Françoise Portaels
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

8.  Anomalous high native resistance to athymic mice to bacterial pathogens.

Authors:  A D Nickol; P F Bonventre
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

9.  Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events.

Authors:  Sheerazed Boulkroun; Laure Guenin-Macé; Maria-Isabel Thoulouze; Marc Monot; Anaïs Merckx; Gordon Langsley; Georges Bismuth; Vincenzo Di Bartolo; Caroline Demangel
Journal:  J Immunol       Date:  2009-12-30       Impact factor: 5.422

10.  Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone.

Authors:  Emmanuelle Coutanceau; Jeremie Decalf; Angelo Martino; Aurélie Babon; Nathalie Winter; Stewart T Cole; Matthew L Albert; Caroline Demangel
Journal:  J Exp Med       Date:  2007-05-21       Impact factor: 14.307

View more
  20 in total

Review 1.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

2.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

3.  Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.

Authors:  Teresa G Martins; José B Gama; Alexandra G Fraga; Margarida Saraiva; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

4.  Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Authors:  Alexandra G Fraga; Teresa G Martins; Egídio Torrado; Kris Huygen; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

5.  Photodegradation of the Mycobacterium ulcerans toxin, mycolactones: considerations for handling and storage.

Authors:  Estelle Marion; Soizic Prado; Camille Cano; Jérémie Babonneau; Sarah Ghamrawi; Laurent Marsollier
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

6.  Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Paul J Converse; Deepak V Almeida; Jihui Zhang; Clive Robinson; Mark Wansbrough-Jones; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14

7.  Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.

Authors:  Teresa G Martins; Gabriela Trigo; Alexandra G Fraga; José B Gama; Adhemar Longatto-Filho; Margarida Saraiva; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS Negl Trop Dis       Date:  2012-11-29

8.  Structure-activity relationship studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans.

Authors:  Nicole Scherr; Philipp Gersbach; Jean-Pierre Dangy; Claudio Bomio; Jun Li; Karl-Heinz Altmann; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28

9.  Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model.

Authors:  Gabriela Trigo; Teresa G Martins; Alexandra G Fraga; Adhemar Longatto-Filho; António G Castro; Joana Azeredo; Jorge Pedrosa
Journal:  PLoS Negl Trop Dis       Date:  2013-04-25

10.  The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER.

Authors:  Belinda S Hall; Kirsti Hill; Michael McKenna; Joy Ogbechi; Stephen High; Anne E Willis; Rachel E Simmonds
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.